For nearly a century, psychiatric diagnoses have been compartmentalized into neatly defined categories: schizophrenia, bipolar disorder, autism spectrum disorders, and others each occupying their own diagnostic “room.” This structural separation shaped clinical practice, informed insurance frameworks, and guided families navigating often perplexing mental health journeys. However, emerging research is challenging these rigid boundaries, revealing a more fluid genetic terrain underpinning these disorders. A groundbreaking study, recently published in Genomic Psychiatry, dives into the shared genetic architecture of serious psychiatric conditions through the lens of multiplex families from the remote Portuguese islands of the Azores and Madeira.
The Azores and Madeira archipelagos represent a unique genetic reservoir. Settled about six centuries ago by a small group of predominantly Portuguese founders and subsequently isolated by geography and history, these islands offer a contained population where rare mutations can stand out sharply against a genetically quieter background. This genetic isolation acts as a natural laboratory enabling researchers to untangle the complexities of inherited psychiatric illness beyond the noise and diversity found in larger populations.
Carlo N. Pato, Michele T. Pato, and their colleagues harnessed this population to assemble the Portuguese Island Collection, a multigenerational archive tracing mental health trajectories within families. Their current analysis focused on 173 families in which multiple members carried serious psychiatric diagnoses. Strikingly, in over 28% of these pedigrees, a single family tree bore both psychotic disorders such as schizophrenia and mood disorders including severe depression and bipolar disorder. Even more intriguing was the overlap uncovered in approximately 7% of families, where autism spectrum disorders and intellectual disability co-occurred alongside psychosis or mood disorders. This revealed that the categories so firmly drawn on diagnostic manuals often blur at the genetic and familial level.
“Our work challenges the artificial divisions between diagnostic categories,” Carlos Pato said. “The genetic and environmental factors that families share allow us to see the inherited architecture of these complex disorders, which large case-control studies—often sweeping and diverse—may obscure.” The approach of studying isolated founder populations thus exposes shared pathways underlying what psychiatry has traditionally viewed as discrete illnesses.
The study’s pivotal revelation arises from a detailed examination of a single three-generation Portuguese family harboring an ultra-rare stop-gain mutation in the CHD2 gene. CHD2 plays a critical role in chromatin remodeling—a process fundamental to brain development. Prior knowledge associates CHD2 primarily with epilepsy and autism risk, but here its impact branches out in unexpected ways. In this family, the exact same genetic variant manifested as schizophrenia in multiple relatives but emerged as autism with intellectual disability in one sibling. This pleiotropy—one gene causing multiple phenotypic outcomes—emphasizes the diverse clinical expressions a single mutation can produce, shaped perhaps by genetic background, environment, or epigenetics.
The rarity of this mutation further underlines its scientific value. It was absent from two large schizophrenia and bipolar disorder genomic databases and detected just once among over 800,000 unrelated individuals in a global genomics catalog. By sequencing multiple family members, the researchers traced inheritance patterns revealing how this variant surfaced as mental illness across generations. An obligate carrier, the father of an affected grandson, though not directly sequenced, had a clinical diagnosis of schizophrenia, reinforcing the mutation’s penetrance within this pedigree.
Michele T. Pato emphasized the power of such family-based investigations: “Rare variants with large effects, observed within broad clinical contexts, give us insights that population-wide databases cannot. They let us ask why the same mutation leads to different clinical illnesses in close relatives. Unraveling this could point directly to novel therapeutic targets.”
Yet, the genetic story is not only about illness. The grandmother in this family carries the exact mutation but remains asymptomatic, a phenomenon known as incomplete penetrance. This contrast invites deep questions about resilience and protective biology. Referencing work by Mayana Zatz, who studied elderly individuals harboring pathogenic mutations without manifesting disease, the researchers highlight the potential for “natural medicine” embedded in such protective mechanisms. Understanding what shields carriers like this grandmother from illness could revolutionize personalized psychiatric treatment.
The authors cautiously interpret their findings within study limitations. Autism was originally excluded as an ascertainment criterion when the collection was initiated, likely leading to underrepresentation of autism spectrum cases. Some key relatives failed sequencing quality control, muddying the precise mutation inheritance map. Moreover, predicted effects of the truncation on the protein’s biochemical behavior remain hypothetical until validated in cellular or animal models. Family sample size and recruitment methods may also influence prevalence estimates, underscoring the need for additional studies to confirm and expand these observations.
This familial genetics approach complements large consortium studies, which have been dissolving traditional diagnostic boundaries from the top down by analyzing vast, heterogeneous populations. While those large studies reveal widespread genetic overlap across psychiatric disorders, the Portuguese Island families uncover the same signal from the bottom up. This convergence from both directions reinforces the notion that major mental illnesses share foundational biological pathways, with distinct clinical manifestations shaped by complex interacting factors.
Editorial commentary accompanying the publication frames the study as a testament to the enduring value of classical genetics in the genomic era. Despite spectacular advances in wide-scale sequencing, truly transformative discoveries often come from carefully revisiting family histories and observing who became ill and how within familial contexts. The authors envision a future where rare variants converge on a few critical biological pathways, yielding novel treatments that transcend narrow diagnostic categories and address the underlying molecular dysfunctions shared across serious mental illnesses.
This study thus represents a milestone in psychiatric genetics, expanding how we understand and ultimately hope to treat these devastating illnesses. By listening closely to the whispers of family trees in isolated populations, researchers have illuminated a genetic landscape far more interconnected and nuanced than previously recognized. Their work exemplifies the integration of population genetics, clinical psychiatry, and molecular biology, pointing the way toward a more personalized and biologically informed psychiatry.
Subject of Research: People
Article Title: Multiplex Portuguese families as a lens into rare mutations and the shared genetic architecture of schizophrenia, mood disorders, and autism spectrum disorders
News Publication Date: 16 June 2026
References:
Pato CN, Pato MT, Mulle J, Hart RP, Pang Z, Knowles JA, et al. Multiplex Portuguese families as a lens into rare mutations and the shared genetic architecture of schizophrenia, mood disorders, and autism spectrum disorders. Genomic Psychiatry 2026. DOI: 10.61373/gp026h.0045
Image Credits: Julio Licinio
Keywords: schizophrenia, mood disorders, autism spectrum disorders, rare mutations, CHD2, genetic architecture, familial genetics, psychiatric genetics, isolated populations, Portuguese islands, multiplex families, pleiotropy
